TOKYO —

Millions of individuals worldwide carry the APOE4 gene variant, recognized as the most potent genetic determinant for Alzheimer’s disease. Emerging research from the Gladstone Institutes is shedding new light on how this genetic predisposition may initiate subtle yet significant alterations in brain activity long before the onset of noticeable memory impairment. This groundbreaking study, published in the esteemed journal Nature Aging, has meticulously mapped a molecular cascade that could elucidate these early pathological effects and, critically, suggests a potential avenue for reversing some of these detrimental changes.

Unraveling the Molecular Mechanism of Early Cognitive Decline

The research team at Gladstone Institutes has identified a specific molecular sequence that appears to be at the heart of APOE4’s early impact on the brain. Their findings indicate that the APOE4 variant significantly elevates the production of a protein known as Nell2. This surge in Nell2 levels, in turn, appears to cause neurons to shrink in size and exhibit unusually high levels of electrical activity, a state termed hyperactivity. Crucially, the study observed a direct correlation: mice exhibiting greater brain hyperactivity during their youth subsequently developed more severe memory deficits as they aged.

This discovery represents a significant leap forward in understanding the preclinical stages of Alzheimer’s. Previously, while elevated brain activity in APOE4 carriers had been noted in humans, the precise cellular and molecular mechanisms driving these changes remained elusive. The Gladstone study provides a tangible link, demonstrating how APOE4 can prime the brain for future cognitive decline through an overactive neuronal network.

The Role of Nell2: A Potential Therapeutic Target

In a pivotal experiment, the researchers demonstrated the reversibility of these APOE4-induced changes. By actively reducing Nell2 production in adult mice already carrying the APOE4 variant, they observed a remarkable return of neuronal size and firing behavior toward normal patterns. This finding offers a beacon of hope, suggesting that future therapeutic interventions specifically targeting Nell2 could potentially mitigate the increased risk of Alzheimer’s disease faced by individuals with the APOE4 gene.

Dr. Misha Zilberter, a principal staff research scientist at Gladstone and a senior author of the study, emphasized the novelty of their findings. "To the best of our knowledge, this is the first study that has directly examined what APOE4 does to the function of neurons at different ages," Dr. Zilberter stated. "We found fundamental changes in brain circuits occurring in young mice that still had normal learning and memory, and importantly, that those changes predicted the development of cognitive deficits at older ages." This underscores the critical importance of intervening at an early, often asymptomatic, stage.

APOE4: A Dominant Genetic Risk Factor

The APOE gene exists in three common forms: APOE2, APOE3, and APOE4. While all play a role in lipid transport and cellular repair in the brain, APOE4 stands out due to its exceptionally strong association with Alzheimer’s disease. Approximately one in four individuals in the general population carries at least one copy of APOE4. This prevalence rises dramatically in individuals diagnosed with Alzheimer’s, with estimates suggesting that 60% to 75% of those affected carry this genetic variant. This statistical linkage has long made APOE4 a focal point of Alzheimer’s research, but understanding its precise molecular impact has been a persistent challenge.

Dr. Yadong Huang, associate director of the Gladstone Institute of Neurological Disease and another senior author on the study, hailed the research as a significant breakthrough. "This study is a big breakthrough for the field of Alzheimer’s research," Dr. Huang remarked. "It opens the door to a better understanding of how APOE4 alters the function of neurons at a young age to increase risk of cognitive decline, and to the development of therapies that could block the detrimental effects of APOE4 early on."

Early Brain Hyperactivity: A Predictive Biomarker

Prior research had already hinted at a state of heightened brain activity in younger individuals who carry the APOE4 gene, even before they experience any cognitive issues. This preclinical hyperactivity has also been linked to a greater likelihood of later-life cognitive decline. However, the underlying reasons for this cellular over-excitation and its contribution to memory problems remained a scientific enigma.

The Gladstone team tackled this question by meticulously analyzing brain activity recordings and individual neurons in young mice. Their investigations revealed that young mice possessing the APOE4 variant exhibited excessive neuronal activity specifically within two key regions of the hippocampus. The hippocampus, a brain structure critically involved in learning and memory formation, is known to be one of the earliest areas affected by Alzheimer’s pathology. Notably, similar patterns of hippocampal hyperactivity have also been observed in human APOE4 carriers.

Dennis Tabuena, PhD, a scientist co-mentored by Drs. Zilberter and Huang, and the first author of the Nature Aging paper, elaborated on these findings. "We found that the extent of hyperactivity in young mice predicted how poorly they performed on spatial learning and memory tests later in life," Dr. Tabuena stated. This direct correlation between early hyperactivity and later cognitive performance provides compelling evidence for a causal link.

Neuronal Size and Excitability: APOE4’s Subtle Influence

To further dissect the mechanism, the researchers compared the brain cells of APOE4-carrying mice with those of mice bearing the APOE3 variant, a form of the gene associated with a lower risk of Alzheimer’s disease. They discovered that neurons in the affected hippocampal regions of APOE4 mice were smaller than those in APOE3 mice. Smaller neurons are generally more sensitive to stimulation, making them more prone to excessive firing.

While hippocampal neurons in APOE3 mice also showed an increase in excitability over time, this phenomenon only emerged in much older animals. In contrast, APOE4 appears to accelerate this process significantly. "This suggests APOE4 accelerates a process that resembles normal aging, and could explain why people with the gene variant are more likely to develop Alzheimer’s disease earlier in life," Dr. Huang explained. This acceleration of age-related changes could be a primary driver of the increased Alzheimer’s risk.

The Crucial Role of Neuronal APOE4 Production

A prevailing hypothesis in Alzheimer’s research had long focused on astrocytes, a type of glial cell that supports neurons, as the primary producers of APOE and the likely culprits behind APOE4’s detrimental effects. This was based on the observation that astrocytes constitute the majority of APOE-producing cells in a healthy brain. However, the new findings from Gladstone challenge this long-held assumption.

The research unequivocally demonstrates that the hippocampal hyperactivity associated with APOE4 is not driven by APOE4 produced by astrocytes, but rather by APOE4 generated within the neurons themselves. This was confirmed through genetic manipulation experiments. "When we deleted the APOE4 gene from astrocytes, nothing changed," Dr. Zilberter reported. "But when we deleted it from neurons, the cells became larger and started functioning normally again." This discovery pivots the focus of research and potential therapeutic strategies towards the intracellular mechanisms within neurons.

Nell2: A Promising Therapeutic Target Emerges

With the intracellular origin of the problem identified, the researchers delved deeper to pinpoint the molecular pathway responsible for APOE4-induced neuronal shrinkage and heightened excitability. They conducted extensive analyses of gene activity patterns within individual cells across various hippocampal cell types in APOE4 mice.

This comprehensive analysis pointed directly to Nell2. The protein was found to be present at unusually high concentrations within neurons carrying the APOE4 variant. To test the hypothesis that elevated Nell2 was the direct cause, the team employed CRISPRi technology, a gene-editing tool that can reduce gene activity without permanently altering the DNA sequence. They used this method to lower Nell2 levels in hippocampal neurons of adult APOE4 mice.

The results were striking: following the reduction of Nell2, the neurons returned to a larger size and exhibited reduced excitability. This confirmed that elevated Nell2 levels are indeed the critical factor driving the excessive neuronal activity observed in APOE4-carrying brains.

While Nell2 had not been previously studied in direct relation to APOE4, independent research had identified elevated levels of this protein in the brains of individuals with Alzheimer’s disease, with higher concentrations correlating with poorer cognitive function. This prior evidence, coupled with the Gladstone findings, solidifies Nell2’s potential as a therapeutic target.

"What’s exciting about Nell2 is that we were able to reverse the disease manifestations in adult mice by lowering its level," Dr. Huang concluded. "That tells us the damage is not irreversible, and that there may be a window for intervention even after disease processes have been triggered." This implies that therapeutic strategies could be effective not only in preventing APOE4-related pathology but also in ameliorating existing damage, offering a crucial opportunity for intervention.

Broader Implications and Future Directions

The implications of this research are far-reaching. For the millions of individuals carrying the APOE4 variant, this study offers a tangible molecular explanation for their increased risk of Alzheimer’s and, more importantly, points towards potential future treatments. The ability to reverse neuronal hyperactivity by targeting Nell2 suggests that interventions might be effective even in later stages of preclinical development, potentially slowing or halting the progression of the disease.

The research was supported by substantial funding from several national health institutes, including the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS). This broad support underscores the significance and potential impact of this line of inquiry.

Future research will likely focus on developing specific Nell2 inhibitors and testing their efficacy and safety in more complex animal models and, eventually, in human clinical trials. Understanding the precise interactions between APOE4, Nell2, and neuronal function will be critical for designing targeted therapies that can effectively protect against or reverse the devastating effects of Alzheimer’s disease. The identification of Nell2 as a key mediator in the APOE4 pathway marks a pivotal moment in the quest to combat this neurodegenerative disorder.